AR109829A1 - Derivados de piperidina puenteados - Google Patents

Derivados de piperidina puenteados

Info

Publication number
AR109829A1
AR109829A1 ARP170102672A ARP170102672A AR109829A1 AR 109829 A1 AR109829 A1 AR 109829A1 AR P170102672 A ARP170102672 A AR P170102672A AR P170102672 A ARP170102672 A AR P170102672A AR 109829 A1 AR109829 A1 AR 109829A1
Authority
AR
Argentina
Prior art keywords
halogen
lower alkyl
hydrogen
lower alkoxy
compounds
Prior art date
Application number
ARP170102672A
Other languages
English (en)
Inventor
Greta Vastakaite
Jrme Charles Sarie
Michael Reutlinger
Hasane Ratni
Werner Neidhart
Anja Limberg
Roland Jakob-Roetne
Bjoern Bartels
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR109829A1 publication Critical patent/AR109829A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente se refiere a un compuesto de fórmula (1), en las que: R¹ es hidrógeno, alquilo inferior, alquilo inferior sustituido con halógeno, halógeno, alcoxi inferior o alcoxi inferior sustituido con halógeno, R¹ puede ser igual o diferente en el caso de que n = 2 ó 3; n es 1, 2 ó 3; m es 1, 2 ó 3; Ar es un grupo heteroarilo de cinco o seis elementos, seleccionado de entre los compuestos del grupo de fórmulas (2), en el que: R² es hidrógeno, alquilo inferior, alquilo inferior sustituido con halógeno, halógeno o alcoxi inferior; R³ es hidrógeno o halógeno; -()ₘ- es -(CH₂)ₘ-; o a sales de adición de ácido farmacéuticamente activas de los mismos. Los compuestos pueden utilizarse para el tratamiento de la enfermedad de Alzheimer, la angiopatía amiloide cerebral, la hemorragia cerebral hereditaria con amiloidosis de tipo holandés (HCHWA-D), la demencia multiinfarto, la demencia pugilística o el síndrome de Down.
ARP170102672A 2016-09-29 2017-09-27 Derivados de piperidina puenteados AR109829A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16191512 2016-09-29

Publications (1)

Publication Number Publication Date
AR109829A1 true AR109829A1 (es) 2019-01-30

Family

ID=57042766

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102672A AR109829A1 (es) 2016-09-29 2017-09-27 Derivados de piperidina puenteados

Country Status (7)

Country Link
US (1) US10899766B2 (es)
EP (1) EP3519418B1 (es)
JP (1) JP7048587B2 (es)
CN (1) CN109790181B (es)
AR (1) AR109829A1 (es)
TW (1) TWI738879B (es)
WO (1) WO2018060300A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018001918A1 (en) * 2016-06-27 2018-01-04 F. Hoffmann-La Roche Ag Triazolopyridines as gamma-secretase modulators
AR109829A1 (es) * 2016-09-29 2019-01-30 Hoffmann La Roche Derivados de piperidina puenteados
EP3743428B1 (en) * 2018-01-22 2022-01-19 F. Hoffmann-La Roche AG Triazolo-azepine derivatives
RS64950B1 (sr) * 2018-09-03 2024-01-31 Hoffmann La Roche Derivati bicikličnog heteroarila
MX2021003773A (es) 2018-10-02 2021-07-16 Frequency Therapeutics Inc Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
MA55611A (fr) 2019-04-08 2022-02-16 Frequency Therapeutics Inc Association de chir99021 et d'acide valproïque pour traiter une perte auditive
CN116568298A (zh) 2020-12-10 2023-08-08 豪夫迈·罗氏有限公司 用于制备4-(3,5-二氟苯基)-N-[3-(6-甲基嘧啶-4-基)-3-氮杂双环[3.2.1]辛烷-8-基]-6,7-二氢-5H-[1,2,4]三唑并[1,5-a]嘧啶-2-胺的方法
JP2023553051A (ja) 2020-12-11 2023-12-20 エフ． ホフマン－ラ ロシュ アーゲー （９Ｓ）－Ｎ－［３－（６－メチルピリミジン－４－イル）－３－アザビシクロ［３．２．１］オクタン－８－イル］－９－（２，３，４－トリフルオロフェニル）－６，７，８，９－テトラヒドロ－５Ｈ－［１，２，４］トリアゾロ［１，５－ａ］アゼピン－２－アミンの調製のための方法、および、その固体形態

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201030002A (en) * 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
US20110190269A1 (en) * 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
US8486967B2 (en) * 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
JP6831372B2 (ja) * 2015-09-09 2021-02-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 架橋ピペリジン誘導体
CN108137579B (zh) * 2015-12-10 2022-01-07 豪夫迈·罗氏有限公司 桥连哌啶衍生物
AR109829A1 (es) * 2016-09-29 2019-01-30 Hoffmann La Roche Derivados de piperidina puenteados
CN109803592B (zh) * 2016-10-06 2022-07-15 波士顿科学国际有限公司 用于可重载止血夹紧装置的部分卵形的囊体
US10941147B2 (en) * 2016-11-01 2021-03-09 Hoffmann-La Roche Inc. Bicyclic heteroaryl derivatives

Also Published As

Publication number Publication date
TWI738879B (zh) 2021-09-11
EP3519418B1 (en) 2021-12-08
US20200031831A1 (en) 2020-01-30
US10899766B2 (en) 2021-01-26
JP2019532948A (ja) 2019-11-14
WO2018060300A1 (en) 2018-04-05
CN109790181B (zh) 2021-05-28
JP7048587B2 (ja) 2022-04-05
EP3519418A1 (en) 2019-08-07
CN109790181A (zh) 2019-05-21
TW201815792A (zh) 2018-05-01

Similar Documents

Publication Publication Date Title
AR109829A1 (es) Derivados de piperidina puenteados
AR110001A1 (es) Derivados heteroarilo bicíclicos
AR107010A1 (es) Derivados de piperidina puenteados
AR105965A1 (es) Derivados de piperidina puenteados
AR074304A1 (es) Moduladores heterociclicos de gamma- secretasa
AR110122A1 (es) Fenoxitriazoles
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
ECSP13012858A (es) Derivados de piperidina puenteada
AR065322A1 (es) 2-aminooxazolinas comoligandos de taar1
AR080083A1 (es) Moduladores de gamma-secretasa
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR102361A1 (es) Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
AR093308A1 (es) Derivados triciclicos fusionados de tiofeno como inhibidores de jak
PE20180030A1 (es) Compuestos biciclicos de sulfonamida cetona
AR088781A1 (es) Compuestos antimicrobianos y metodos para prepararlos y utilizarlos
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR091939A1 (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
PE20151509A1 (es) Derivado de piridina monociclico
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
CU23706B7 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
AR092749A1 (es) Compuestos farmaceuticos
AR101359A1 (es) Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo
AR094159A1 (es) Compuesto de [1,2,4]triazol e imidazol sustituidos
AR115464A1 (es) Compuestos para el tratamiento, alivio o prevención de trastornos asociados con los agregados de tau